LISI 61.000 € (+0,33 %)
VALLOUREC 18.865 € (+1,21 %)
MAAT PHARMA 2.880 € (-2,04 %)
TOTALENERGIES 77.300 € (+1,58 %)
WORLDLINE 14.212 € (-2,31 %)
GTT 220.000 € (+1,76 %)
EUROPLASMA 0.001 € (+33,33 %)
ASR NEDERLAND 73.960 € (-0,62 %)
SHOWROOMPRIVE 1.050 € (+9,38 %)
SHELL PLC 40.560 € (+1,13 %)
ARKEMA 59.050 € (-0,42 %)
SARTORIUS STED BIO 186.500 € (-2,00 %)
MERSEN 38.700 € (+2,54 %)
ALSTOM 16.300 € (-1,21 %)
SAINT GOBAIN 74.620 € (-1,53 %)
VINCI 113.600 € (-0,31 %)
EXOSENS 57.450 € (+4,08 %)
MICHELIN 34.470 € (-1,96 %)
BENETEAU 5.690 € (-1,39 %)
SOLUTIONS 30 SE 0.538 € (-0,55 %)
CROSSJECT 1.400 € (+4,48 %)
ADP 108.200 € (-1,10 %)
RIBER 9.480 € (+10,75 %)
ARCADIS 43.980 € (-0,99 %)
ROBERTET 791.000 € (-0,75 %)
BNP PARIBAS ACT.A 104.540 € (0,00 %)
CARREFOUR 16.270 € (-0,82 %)
TETRAGON FIN GRP 14.100 € (+0,71 %)
CRCAM BRIE PIC2CCI 37.200 € (+0,54 %)
AMG 32.660 € (+3,55 %)
KERING 241.400 € (-1,55 %)
CASINO GUICHARD 0.184 € (-0,16 %)
ESSILORLUXOTTICA 148.550 € (-0,83 %)
ACCOR 46.650 € (-0,53 %)
IMERYS 24.660 € (+1,40 %)
PHARMING GROUP 0.982 € (+1,34 %)
ATOS GROUP 26.220 € (-2,24 %)
HAFFNER ENERGY 0.668 € (+12,84 %)
SCHNEIDER ELECTRIC 295.500 € (+2,60 %)
VICAT 65.700 € (+0,31 %)
AKZO NOBEL 60.160 € (-0,95 %)
AHOLD DEL 31.100 € (-1,77 %)
PARROT 9.250 € (-1,28 %)
SPIE 43.780 € (-0,05 %)
ABN AMRO BANK N.V. 43.420 € (+0,67 %)
WINFARM 3.900 € (0,00 %)
WAVESTONE 31.800 € (-1,24 %)
SOITEC 143.350 € (+11,73 %)
ARCELORMITTAL SA 67.540 € (+0,45 %)
SOCIETE GENERALE 75.070 € (+1,20 %)
ALTAREA 88.700 € (-2,53 %)
KAUFMAN ET BROAD 22.550 € (-2,38 %)
ARGAN 72.400 € (-1,76 %)
SANOFI 75.690 € (-0,75 %)
CREDIT AGRICOLE 18.865 € (+0,32 %)
CTP 13.700 € (-1,30 %)
AMOEBA 0.629 € (+0,64 %)
OMER-DECUGIS & CIE 8.400 € (0,00 %)
AXA 44.160 € (-1,08 %)
ASM INTERNATIONAL 862.200 € (+4,48 %) |
02/09/2026 09:40
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to participate in trial for innovative mapping and pulsed field ablation systemEQS-News: Texas Cardiac Arrhythmia Institute at St. David's Medical Center / Key word(s): Miscellaneous AUSTIN, Texas, Sept. 2, 2026 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the nation to participate in a clinical trial to evaluate the safety and effectiveness of a next-generation mapping and pulsed field ablation system to treat patients with paroxysmal and persistent atrial fibrillation. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., executive medical director of TCAI and the global principal investigator for the trial, performed the first procedure. Atrial fibrillation, the most common type of arrhythmia, affects millions of people globally. It occurs when the top two chambers of the heart beat too fast and with an irregular rhythm. Paroxysmal atrial fibrillation is an arrhythmia with symptoms that last for seven days or fewer, while persistent atrial fibrillation is a sustained arrhythmia that lasts for more than a week. Early treatment of paroxysmal and persistent atrial fibrillation can reduce the risk of blood clots, stroke and heart failure—and may prevent the disease from becoming permanent. "Pulsed field ablation represents one of the most significant advancements in electrophysiology in decades, and this clinical trial will help physicians around the world better understand the safety and effectiveness of this technology," Dr. Natale said. "The Texas Cardiac Arrhythmia Institute remains at the forefront of arrhythmia care, helping to advance technologies that will shape the future of electrophysiology." The novel catheter system relies on electric fields to ablate targeted heart tissue without using the excess heat or cold used in traditional ablation, helping to reduce the risk of damage to surrounding structures. The system incorporates advanced 3D cardiac mapping technology that provides a detailed view of the heart's electrical activity, enabling physicians to visualize catheter position and tissue contact before and after the energy is delivered. During a traditional ablation procedure, a catheter is guided into the interior of the heart and uses extreme heat or cold to destroy tissue associated with abnormal heart rhythms, creating a greater chance that surrounding structures will be damaged. TCAI is a state-of-the-art Electrophysiology Center that includes six labs equipped with advanced technology where a group of renowned cardiac electrophysiologists perform a high volume of the most complex electrophysiology procedures. ![]() 02.09.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2392578 02.09.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
